Varda Raises $250M for Orbital Drug Manufacturing
Varda's latest raise pushes space manufacturing closer to a commercial infrastructure story, not just a launch story.
Varda is turning microgravity from a scientific curiosity into a potential manufacturing platform.
What happened
Varda Space raised a $250 million Series D at a $1.6 billion valuation, bringing its total capital raised to roughly $598 million. The round was led by Lux Capital and Natural Capital.
The company builds recoverable orbital capsules designed to process materials in microgravity and then bring them back to Earth. Its most visible use case is pharmaceutical manufacturing, where microgravity can affect how drug crystals form. Varda has flown six missions since 2023, giving it more operational evidence than many early commercial-space manufacturing startups.
Why it matters
Commercial space has mostly been framed around launch, satellites, communications and defence. Varda is pushing a different thesis: space can become a production environment. If microgravity manufacturing proves commercially useful, the addressable market expands beyond moving objects into orbit and toward making high-value materials there.
That is especially relevant for drug development, where small changes in crystal structure can affect formulation, delivery and performance. The valuation also suggests investors are willing to back space companies with industrial use cases rather than only infrastructure or national-security demand.
The bigger picture
The next stage for space startups is proving that orbital activity can generate repeatable commercial value on Earth. Varda still needs to show that space-made products can scale economically, but its funding round shows that microgravity manufacturing is becoming one of the sector’s clearest non-launch bets.